Notice of cessation of manufacture, distribution and supply of
SINEMET® CR (carbidopa levodopa)

July 16, 2019

Dear Healthcare Professional:

This is to inform you that Merck will discontinue the manufacturing, distribution and supply of SINEMET CR, effective July 2019. This decision is not related to a product quality or safety issue.

We anticipate that supply of SINEMET CR will remain available in the U.S. on or near November 2019 for SINEMET CR 50/200 mg and on or near February 2020 for SINEMET CR 25/100 mg; however, this date may change, based on any increase or decrease in demand for SINEMET CR in the next few months.

Merck understands that decisions like this may cause challenges for patients, and we carefully evaluate the impact of any decision to discontinue manufacturing a product. The company's decision to discontinue SINEMET CR is based on two factors: supply chain challenges and the fact that there are currently alternative treatments including generic equivalents to both products available to physicians and their patients.

As noted above, there is no impact to the quality or safety of SINEMET CR currently on the market and in use by patients. Although manufacturing operations have ceased, remaining inventory of SINEMET CR will continue to be supplied to the marketplace until it is exhausted. We would advise, however, that you begin discussing appropriate alternative therapies with your patients and/or transitioning your patients to an appropriate alternative therapy as soon as possible.

We regret any inconvenience this may cause you and your patients.

Please contact the Merck National Service Center Telephone Number: 1-800-672-6372 for any further questions.

Anne E. de Papp, MD
Vice President & Head, U.S. Medical Affairs